dapagliflozin + rosuvastatin placebo

Dapagliflozin + rosuvastatin placebo is a clinical trial comparator arm used to evaluate the efficacy and safety of the fixed-dose combination CMG190303 (dapagliflozin/rosuvastatin). Developed by CMG Pharmaceutical Co. Ltd., this intervention consists of active dapagliflozin (10 mg) and an inactive placebo for rosuvastatin. It is utilized in Phase 3 trials (such as NCT06772168) targeting patients with comorbid type 2 diabetes mellitus and dyslipidemia. Dapagliflozin is a small molecule inhibitor of the sodium-glucose cotransporter-2 (SGLT2), which reduces blood glucose levels by inhibiting renal glucose reabsorption and promoting its excretion in the urine. The rosuvastatin placebo serves to maintain the double-blind nature of the study while isolating the effects of dapagliflozin alone.

Other names

Comparator 1: Dapagliflozin/Rosuvastatin placebodapagliflozin 10mg + rosuvastatin placebo